{
    "N/R/U": null,
    "Applicant": "Sandoz Inc.",
    "BLA Number": "761165",
    "Proprietary Name": "Cimerli",
    "Proper Name": "ranibizumab-eqrn",
    "BLA Type": "351(k) Interchangeable",
    "Strength": "10MG/ML (0.5MG/0.05ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Intravitreal",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "August 02, 2022",
    "Ref. Product Proper Name": "ranibizumab",
    "Ref. Product Proprietary Name": "Lucentis",
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "2003",
    "Product Number": "001",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": "October 3, 2023",
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}